Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot Study

Next Previous
Trial Profile

Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot Study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belumosudil (Primary) ; Corticosteroids; Mycophenolate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

Most Recent Events

  • 22 May 2024 Status changed from recruiting to active, no longer recruiting.
  • 14 Aug 2023 Planned End Date changed from 1 Apr 2025 to 1 Aug 2026.
  • 14 Aug 2023 Planned primary completion date changed from 1 Apr 2025 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top